Learn how bronchiectasis affects more than just your lungs, from heart health and bone density to mental well-being and cognitive risks.

The dipeptidyl peptidase-1 (DPP1) inhibitor brensocatib became the first licensed therapy for bronchiectasis in the USA and Europe in 2025,1 based on the phase 3 ASPEN trial showing an approximate 20% ...

An updated December 2025 ERS clinical practice guideline provides evidence-based recommendations for managing adult ...

In patients with CF, pre-transplant PH is associated with improved early post-transplant survival, but with poorer outcomes after 3 years.

This chronic lung condition causes your airways to become permanently widened and scarred. Learn how to spot and treat this ...

Brensocatib, the first FDA-approved medication to treat non-cystic fibrosis bronchiectasis, can reduce symptoms of the ...

If you have bronchiectasis, the essential goal of treatment is to keep your airway clear. Bronchiectasis is a chronic lung condition in which the airways become widened and damaged, making it harder ...

Electromed ( (ELMD)) just unveiled an update. Electromed, Inc., a medical device maker specializing in airway clearance systems such as its SmartVest® product for patients with chronic pulmonary ...

Miami (October 23, 2025) – The Bronchiectasis and NTM Association announced today that two abstracts using Bronchiectasis and NTM Research Registry data were presented at CHEST 2025, held October ...

Insmed Incorporated, a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, announced that ...

BRIDGEWATER, N.J. - The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Insmed’s BRINSUPRI (brensocatib) for treating non-cystic fibrosis ...